Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-Current Deffered Revenue: 2015-2019

Historic Non-Current Deffered Revenue for Outlook Therapeutics (OTLK) over the last 3 years, with Jun 2019 value amounting to $3.5 million.

  • Outlook Therapeutics' Non-Current Deffered Revenue rose 15.41% to $3.5 million in Q2 2019 from the same period last year, while for Jun 2019 it was $3.5 million, marking a year-over-year increase of 15.41%. This contributed to the annual value of $2.8 million for FY2018, which is 38.25% down from last year.
  • Per Outlook Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $3.5 million for Q2 2019, which was down 14.18% from $4.1 million recorded in Q1 2019.
  • Outlook Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $12.7 million during Q3 2015, with a 5-year trough of $2.8 million in Q3 2018.
  • Its 3-year average for Non-Current Deffered Revenue is $3.9 million, with a median of $4.1 million in 2017.
  • Per our database at Business Quant, Outlook Therapeutics' Non-Current Deffered Revenue slumped by 59.51% in 2016 and then grew by 23.46% in 2019.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Non-Current Deffered Revenue stood at $12.7 million in 2015, then plummeted by 59.51% to $4.9 million in 2016, then fell by 16.87% to $4.0 million in 2017, then grew by 16.58% to $4.7 million in 2018, then climbed by 15.41% to $3.5 million in 2019.
  • Its Non-Current Deffered Revenue was $3.5 million in Q2 2019, compared to $4.1 million in Q1 2019 and $4.7 million in Q4 2018.